Full-Time

Associate Director

ERP Functional & Solutions Architect-D365

Kyowa Kirin

Kyowa Kirin

1,001-5,000 employees

Global specialty pharma leveraging fermentation and antibodies

Compensation Overview

$165k - $190k/yr

Princeton, NJ, USA

Hybrid

Category
Sales & Solution Engineering (1)
Required Skills
Inventory Management
Machine Learning
Requirements
  • Bachelor’s degree or equivalent experience in computer science, information systems, engineering, supply chain, or related fields required
  • Microsoft D365 F&O Certification preferred
  • 8+ years of experience implementing or supporting Microsoft Dynamics AX / D365 F&O
  • Proven expertise across multiple functional domains (Finance, Manufacturing, Supply Chain, Procurement)
  • Experience designing integrations between ERP and external systems (LIMS, MES, Payment interface with Bank, External Finance Systems, etc.)
  • Strong understanding of ERP data models, workflows, and reporting
  • Strong understanding of functional and solution architecture of, and experience performing code and configuration updates within the following Dynamics 365 modules: Finance: General ledger, Cash and bank management, Accounts payable, Accounts receivable; Budgeting, Fixed assets, Cost accounting, PR/PO process, Vendor Management, Cost Accounting and Management; SCM: Inventory management, Master planning, Procurement and sourcing, Product information management, Production control, Warehouse management, Cost accounting, Cost management, Asset management, including scheduled maintenance and repair tasks
  • Proficient in MS Office Suite. Experience with technology delivery applications across solutions such as ERP, Manufacturing Execution Systems, Finance Systems, Control Tower
  • Microsoft Certified: Dynamics 365: Finance and Operations Apps Solution Architect Expert certification preferred
  • Experience with emerging technologies (AI/ML, cloud, etc.) as relevant to ERP
Responsibilities
  • Lead the functional design and architecture of the D365 F&O solution across key modules (Finance, Supply Chain, Manufacturing, Procurement, Inventory, Quality, etc.)
  • Translate complex business requirements into clear, scalable, and compliant functional solutions
  • Emphasizes proactive, holistic leadership in solution architecture
  • Focuses on aligning solutions with business goals, value streams, and enterprise architecture governance
  • Define data flows, integrations, and system interactions between D365 and other enterprise systems & interfaces (e.g., LIMS, MES, 3PL Partners, External Finance Systems, and Cloud systems)
  • Ensure alignment with Microsoft’s Dynamics 365 roadmap and best practices
  • Perform and lead the setup, configuration, and deployment of D365 F&O modules
  • End to end management of project/solution management by using tools like Azure Boards for planning and tracking work, Azure Repos for code versioning, and Azure Pipelines for automating build and deployment. Perform all activities from initial user stories and tasks to code, testing, and deployment through integrations with tools like Lifecycle Services (LCS)
  • Drive fit-gap analysis and functional documentation. Develop User/Functional Requirements, Functional/Technical Design, System/Business process architecture diagrams
  • Collaborate with development/vendor/managed service teams to define functional specifications for enhancements, bug/fix, customizations, reports, and interfaces. Co-develop or individually develop code/configurations required and coordinate internal development and user acceptance testing of the solution
  • Participate in system validation activities, including IQ/OQ/PQ documentation for regulated environments
  • Ensure the ERP system design complies with GAMP 5, SOX, and GxP regulatory requirements
  • Develop and maintain master data governance, change management, and configuration control processes
  • Support audits and inspections through proper documentation and traceability
  • Develop current and future state roadmaps and architecture
  • Assess and align system release plan with Microsoft Dynamics 365 roadmap
  • Partner with business process owners to define best practices, continuous improvement opportunities, and confirm desired solution to fix the support/bug-fix items raised
  • Support communities of practice and collaborative development methodology
  • Work independently to perform required fix within the D365 framework. Test and confirm the developed fix with business process owners
  • Work closely with IT, OT, and cloud teams to ensure integrated digital architecture
  • Provide subject matter expertise and training for internal business process owners and super users
  • Support ERP implementation and upgrade projects through all phases — initiation, design, testing, go-live, and hypercare
  • Manage and coordinate external implementation partners and vendors
  • Define KPIs and monitor system performance, adoption, and ROI
Desired Qualifications
  • Microsoft D365 F&O Certification preferred
  • Microsoft Certified: Dynamics 365: Finance and Operations Apps Solution Architect Expert certification preferred

Kyowa Kirin is a global specialty pharmaceutical company that develops medicines using fermentation and antibody technologies. Its products target areas like nephrology, oncology, and immunology, with therapies built from biologics and other drug modalities. The company emerged from a merger between Kyowa Hakko Kogyo and Kirin Pharma, combining Kyowa’s fermentation and microbiology expertise with Kirin’s pharma resources to create a worldwide focus on specialty drugs. Unlike broader drug companies, Kyowa Kirin concentrates on a defined set of indications and runs a research-and-development-led business that aims to deliver innovative treatments for patients in need.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1885

Simplify Jobs

Simplify's Take

What believers are saying

  • Libmeldy commercialization in MLD expands rare disease revenue streams globally.
  • Orchard pipeline programs in MPS, FTD, Crohn's disease address high unmet needs.
  • North Carolina manufacturing capacity supports cell and gene therapy market growth.

What critics are saying

  • Libmeldy reimbursement denial in UK, Germany, US collapses primary revenue driver.
  • Orchard pipeline failures in Phase 2/3 trials eliminate $478M acquisition rationale.
  • Gene therapy manufacturing delays at Sanford facility constrain supply and revenue ramp.

What makes Kyowa Kirin unique

  • 75+ years fermentation expertise underpins proprietary antibody and gene therapy platforms.
  • Orchard Therapeutics acquisition adds Libmeldy gene therapy for rare genetic diseases.
  • $530M Sanford biologics facility enables scaled manufacturing of advanced cell therapies.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Kyowa Kirin who can refer or advise you

Benefits

401(k) Company Match

Paid Vacation

Paid Sick Leave

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Hybrid Work Options

Pet Insurance

Tuition Assistance

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

-1%

2 year growth

-1%
Benzinga
Dec 15th, 2025
Link Cell Therapies raises $92M to advance CAR-T cancer treatments for solid and liquid tumors

Link Cell Therapies has emerged from stealth with $60 million in Series A funding led by Johnson & Johnson Innovation – JJDC, bringing total capital raised to $92 million. The South San Francisco–based oncology company is developing CAR-T therapies for solid and liquid tumours using proprietary logic-gating technology. The platform enables safe targeting of multiple antigens co-expressed on cancer cells whilst sparing healthy tissue. Co-founded by Dr Robbie Majzner and Dr Crystal Mackall at Stanford University in 2022, Link's lead programme, LNK001 for renal cell carcinoma, is on track for an IND application and Phase I trial in 2026. The Series A round included participation from founding investors Samsara BioCapital and Sheatree Capital, alongside new backers Bristol Myers Squibb, Kyowa Kirin and Wing Venture Capital.

FinSMEs
Mar 4th, 2025
Garuda Therapeutics Closes $50M Series A-1 Financing

Garuda Therapeutics, a Cambridge, MA-based hematopoietic stem cell (HSC) therapies company, raised $50M in Series A-1 funding

Cimeio Therapeutics
Dec 10th, 2024
Cimeio Therapeutics Announces Partnership with Kyowa Kirin to Develop Novel Cell Therapies

The partnership combines Cimeio's proprietary Shielded Cell and Immunotherapy (SCIP) platform with Kyowa Kirin's expertise in cellular therapies and underscores both companies' commitment to using emerging cell and gene therapy technologies to develop new ways to treat patients.

Business North Carolina
Nov 27th, 2024
Op/ed: Biotech's role in North Carolina's job-creation success

Kyowa Kirin, a Japanese global specialty pharmaceutical company, plans to invest more than $200 million in Sanford to build its first pharmaceutical manufacturing complex in North America, adding more than 100 new jobs.

World Pharmaceutical Frontiers
Jun 11th, 2024
Kyowa Kirin to establish new $530m biologics manufacturing plant in US

Japan-based Kyowa Kirin has unveiled its plans to invest $530m to build a new advanced biologics manufacturing facility in Sanford in the American state of North Carolina.